“Natural Killer” Cell Oncoimunotherapy carrying antigen hysteric receptors (Q3099129)

From EU Knowledge Graph
Revision as of 13:31, 6 October 2021 by DG Regio (talk | contribs) (‎Removed claim: beneficiary (P889): (Q3118623))
Jump to navigation Jump to search
Project Q3099129 in Romania
Language Label Description Also known as
English
“Natural Killer” Cell Oncoimunotherapy carrying antigen hysteric receptors
Project Q3099129 in Romania

    Statements

    0 references
    7,171,850.97 Romanian Leu
    0 references
    1,434,370.1940000001 Euro
    13 September 2021
    0 references
    8,493,897.32 Romanian Leu
    0 references
    1,698,779.4640000002 Euro
    13 September 2021
    0 references
    84.44 percent
    0 references
    1 September 2016
    0 references
    30 November 2020
    0 references
    SPITALUL CLINIC JUDETEAN DE URGENTA " PIUS BRINZEU " TIMISOARA
    0 references
    Obiectivul principal al acestei propuneri de proiect este de a urma o abordare unica si de a dezvolta noi CARs care sunt potrivite în mod special pentru terapiile pe baza de celule NK, care reprezinta terapia personalizata anti-tumorala de ultimă ora. Ne asteptam ca acest proiect sa produca cereri de brevet internationale, care se vor traduce in cele din urma in comercializarea acestei tehnologii in Romania si in strainatate. Cunostintele obtinute in urma cercetarilor fundamentale in acest domeniu vor servi ulterior la stabilirea procedurile de lucru, reproductibile care vor ghida productia la nivel de GMP de celule pentru uz clinic pentru studii clinice suplimentare. In plus, ne propunem crearea primei banci de celule umane CAR-NKS, care poate fi dezvoltata si utilizata pentru studii clinice, in sprijinul medicinii personalizate in Romania. (Romanian)
    0 references
    The main objective of this project proposal is to follow a unique approach and develop new CARs that are especially suitable for NK cell therapies, which represent the latest personalised anti-tumor therapy. We expect this project to produce international patent applications, which will ultimately translate into the commercialisation of this technology in Romania and abroad. The knowledge obtained from fundamental researches in this field will then serve to establish reproducible working procedures that will guide the production of GMP cells for clinical use for further clinical trials. In addition, we aim to create the first CAR-NKS human cell bank, which can be developed and used for clinical trials, in support of personalised medicine in Romania. (English)
    16 September 2021
    0 references
    Municipiul Timişoara, Romania
    0 references

    Identifiers

    103662
    0 references